Clinical impact of novel treatment strategies. - Wikidata - awgldk - TriplyDB

Clinical impact of novel treatment strategies.

Clinical impact of novel treatment strategies.

http://www.wikidata.org/entity/Q34936052

about

The molecular basis of lung cancer: molecular abnormalities and therapeutic implications Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line.Targeted Therapies in Lung Cancer.High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications.Mass spectrometry-based proteomic profiling of lung cancer.Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy.Mesenchymal stem cells as vectors for lung disease Exhaled pentane as a possible marker for survival and lipid peroxidation during radiotherapy for lung cancer--a pilot study.A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer.PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin

P2860

Q24802445-19BFA313-534C-4771-8787-2E6E003112B2 Q28536191-FA02CE90-87EB-40C6-8A8B-2BD663F7729C Q33727478-8EC44303-D0BF-4E1E-B9D5-8FF8A2EFDBCA Q34030379-B4CFC4FE-CFFF-4555-9463-D33A9CE5522E Q36288148-62A24D02-C816-4018-AE09-AB44135B7412 Q37171914-274B7542-3D5C-4A32-9DF3-F3EF595B6366 Q37214261-418C81B8-0CC6-41D2-8342-D39FE9C85D19 Q37236694-E05C45CA-846E-4BE5-A07D-2E8892BC5B8F Q43294336-DE93A9C8-115E-40CE-A314-9DEFB3952883 Q45949842-502B4267-8E4B-48CE-ADE6-959609782864 Q58799114-97A5077A-113F-4375-81E3-C203B514EB2B

P2860

Clinical impact of novel treatment strategies.

http://www.wikidata.org/entity/Q34936052

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Clinical impact of novel treatment strategies.

@ast

Clinical impact of novel treatment strategies.

@en

Clinical impact of novel treatment strategies.

@nl

type

label

Clinical impact of novel treatment strategies.

@ast

Clinical impact of novel treatment strategies.

@en

Clinical impact of novel treatment strategies.

@nl

prefLabel

Clinical impact of novel treatment strategies.

@ast

Clinical impact of novel treatment strategies.

@en

Clinical impact of novel treatment strategies.

@nl

P1433

Q34936052-B4CDE567-160D-4730-96F8-CE64993C01C8

P1476

Q34936052-61AE4109-9672-4221-9B45-DCCFDF36B7A4

P2093

Q34936052-AF0DF090-A8E9-4211-89FE-32488003915C

P2860

Q34936052-02217B02-FB3D-4819-9CF1-868D0E94969E

Q34936052-0E4EE9B0-6E36-4FC8-990F-3E62EFFFAC8E

Q34936052-100B9042-2888-4A6C-85EB-5BD25671C550

Q34936052-10475210-11EE-4D3A-AA24-CB161E1D07DC

Q34936052-1296DC52-86EA-48F7-A609-A1E2C7ED79D5

Q34936052-1309ED6D-C5D4-427B-800E-8B2B9984272E

Q34936052-1DCAB459-0A25-4B57-A88A-24512881340D

Q34936052-1E569FDF-3F98-4224-A60E-6C6465B13BAB

Q34936052-20C38070-24C7-43B6-ABEF-C432D1D1A8F8

Q34936052-213AB739-1358-4A4A-8371-348782C74FB9

P2888

Q34936052-7B5C1D90-B75E-4C11-B03B-BCDB4616CB68

P304

Q34936052-76F70856-EFE4-4B0D-A3D7-5E8C4349667C

P31

Q34936052-681D81B2-571B-4DEF-8E5F-A368CBD7E4CA

P356

Q34936052-DA733A07-A3E7-4154-9EEF-7F0BBE2CE415

P407

Q34936052-D77FDC5C-97B6-4B31-A8D6-60AB71CA9D24

P433

Q34936052-393F1FC7-3D88-429F-9F1B-7E2F8260689A

P478

Q34936052-E45F04C3-66B6-41D2-9C3B-E1B1C3068063

P577

Q34936052-11221598-0145-4409-837F-05767140B4CE

P5875

Q34936052-78FFB9D0-8761-4C2A-9371-98B0A08F74C7

P6179

Q34936052-8E5C46CE-3298-42E7-9951-D09C94424194

P698

Q34936052-39920E13-AB1E-4D39-8C0A-94A4497EEBE5

P356

P1433

P1476

Clinical impact of novel treatment strategies.

@en

P2093

Giuseppe Giaccone

http://www.w3.org/2001/XMLSchema#string

P2860

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.

Epidermal growth factor-related peptides and their receptors in human malignancies

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Chronic oral administration of CI-994: a phase 1 study.

Gene therapy for lung cancer.

P2888

P304

6970-6981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1205565

http://www.w3.org/2001/XMLSchema#string

P407

P433

45

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11096157

http://www.w3.org/2001/XMLSchema#string

P6179

1017010624

http://www.w3.org/2001/XMLSchema#string

P698

12362278

http://www.w3.org/2001/XMLSchema#string